MarginsXMarginsX
Home › Markets › Health Care › ATTO

Attovia Therapeutics Inc. (ATTO)

ATTO trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$14.72
-2.68% on the day
Market cap
$673.1M
Small cap
Revenue
New registrant: no annual report filed under this company yet
Net income
New registrant: no annual report filed under this company yet

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerATTO on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO year2026
SEC CIK0002058707
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inDE

Financials

New registrant: no annual report filed under this company yet.

Warning signs

Cash runway
17.0 months
$115.4M cash at September 30, 2026
Share count, 1 year
No year-earlier count
Going-concern doubt
No
10-Q filed November 9, 2026
Insider net buying, 12 months
$39.8M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-09
Cash and burn$115.4M cash; operating cash flow -$20.4M a quarter.Report 2026-09-30
Shares outstanding45,712,536 (2026-10-31).Cover page 2026-10-31
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorPricewaterhouseCoopers LLP, San Jose, California, United StatesPCAOB Form AP 2026-08-07
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $42.1M, sold $2.2M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$0-$22.3M-$25.7M$115.4MNo debt tagsNeeds four quarters10-Q 2026-11-09
Q2 2026
2026-06-30
$450K-$20.7MNot filed$32.8MNo debt tagsNeeds four quarters10-Q 2026-09-02
Q3 2026
2026-03-31
Not filed-$18.7MNot filedNot filedNo debt tagsNeeds four quarters10-Q 2026-11-09
Q3 2026
2025-09-30
$360K-$13.8M-$15.2M$49.8MNo debt tagsNeeds four quarters10-Q 2026-11-09
Q2 2026
2025-06-30
$0-$14.4MNot filed$42.6MNo debt tagsNeeds four quarters10-Q 2026-09-02
Q3 2026
2025-03-31
Not filed-$15.2MNot filedNot filedNo debt tagsNeeds four quarters10-Q 2026-11-09

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B42026-08-05
Latest quarterly / interim10-Q2026-11-09
Latest current report8-K2026-11-09

Source: SEC EDGAR submissions feed, 61 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-0.9%
1 month+2.8%
3 months-21.1%
Year to dateNot enough price history
1 yearNot enough price history
From 52-week high-40.8%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
DBVTDBV Technologies S.A.$10.27-6.76%$645.8M
BBTXBambusa Therapeutics Inc.$15.98-0.68%$645.4M
FDMT4D Molecular Therapeutics Inc.$11.29-7.69%$636.5M
SLDBSolid Biosciences Inc.$6.48-5.26%$723.2M
CGEMCullinan Therapeutics Inc.$9.50-7.59%$616.7M
SRZNSurrozen Inc.$32.32+2.25%$616.1M
AURAAura Biosciences Inc.$7.22+1.55%$751.4M
PRMEPrime Medicine Inc.$4.19-1.87%$762.3M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier